Hematologic complications of pregnancy

Seminars in Hematology

Volumn 50, Issue 3, 2013, Pages 222-231

  Townsley, Danielle M ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DESMOPRESSIN; FIBRINOGEN; FOLIC ACID; FONDAPARINUX; HEPARIN; IMMUNOGLOBULIN G; IRON; LOW MOLECULAR WEIGHT HEPARIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RHESUS D ANTIBODY; RITUXIMAB; TRANEXAMIC ACID; VON WILLEBRAND FACTOR;

APLASTIC ANEMIA; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; BLOOD CELL COUNT; BLOOD CLOTTING; BLOOD CLOTTING FACTOR 11 DEFICIENCY; BLOOD CLOTTING FACTOR 13 DEFICIENCY; BLOOD GROUP ABO SYSTEM; BLOOD TRANSFUSION; CRYOPRECIPITATE; FACTOR V LEIDEN GENE; FEMALE; FIBRINOGEN DEFECT; FOLIC ACID DEFICIENCY; GENE MUTATION; HELLP SYNDROME; HEMATOLOGIC DISEASE; HEMOPHILIA; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; IMMUNE THROMBOCYTOPENIA; IRON DEFICIENCY ANEMIA; IRON INTAKE; IRON THERAPY; MATERNAL HYPERTENSION; MEGALOBLASTIC ANEMIA; MORTALITY; NEONATAL ALLOIMMUNE THROMBOCYTOPENIA; PARTIAL THROMBOPLASTIN TIME; POSTPARTUM HEMORRHAGE; PREECLAMPSIA; PREGNANCY COMPLICATION; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL; SICKLE CELL ANEMIA; THROMBOCYTE DISORDER; THROMBOCYTOPENIA; THROMBOPHILIA; THROMBOSIS PREVENTION; THROMBOTIC THROMBOCYTOPENIC PURPURA; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM; VON WILLEBRAND DISEASE;

ANEMIA; BLOOD COAGULATION DISORDERS; FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; THROMBOCYTOPENIA; THROMBOEMBOLISM;

EID: 84881588973     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2013.06.004     Document Type: Article

References (74)

1. Sifakis S., Pharmakides G. Anemia in pregnancy. Ann N Y Acad Sci 2000, 900:125-136.
2. Trumbo P., Yates A.A., Schlicker S., Poos M. Dietary reference intakes: vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium, and zinc. J Am Diet Assoc 2001, 101(3):294-301.
3. Screening for Iron Deficiency Anemia in Childhood and Pregnancy: Update of the 1996 U.S. Preventive Task Force Review. Rockville (MD). 2006.
4. Cogswell M.E., Parvanta I., Ickes L., Yip R., Brittenham G.M. Iron supplementation during pregnancy, anemia, and birth weight: a randomized controlled trial. Am J Clin Nutr 2003, 78(4):773-781.
5. Christian P., West K.P., Khatry S.K., et al. Effects of maternal micronutrient supplementation on fetal loss and infant mortality: a cluster-randomized trial in Nepal. Am J Clin Nutr 2003, 78(6):1194-1202.
6. Khalafallah A., Dennis A., Bates J., et al. A prospective randomized, controlled trial of intravenous versus oral iron for moderate iron deficiency anaemia of pregnancy. J Intern Med 2010, 268(3):286-295.
7. Froessler B., Cocchiaro C., Saadat-Gilani K., Hodyl N., Dekker G. Intravenous iron sucrose versus oral iron ferrous sulfate for antenatal and postpartum iron deficiency anemia: a randomized trial. J Matern Fetal Neonat 2012, 7:654-659.
8. Scanlon K.S., Yip R., Schieve L.A., Cogswell M.E. High and low hemoglobin levels during pregnancy: differential risks for preterm birth and small for gestational age. Obstet Gynecol 2000, 96(5 Pt 1):741-748.
9. Scholl T.O. Iron status during pregnancy: setting the stage for mother and infant. Am J Clin Nutr 2005, 81(5):1218S-1222S.
10. Smith J.A., Espeland M., Bellevue R., Bonds D., Brown A.K., Koshy M. Pregnancy in sickle cell disease: experience of the Cooperative Study of Sickle Cell Disease. Obstet Gynecol 1996, 87(2):199-204.
11. Serjeant G.R., Loy L.L., Crowther M., Hambleton I.R., Thame M. Outcome of pregnancy in homozygous sickle cell disease. Obstet Gynecol 2004, 103(6):1278-1285.
12. Sun P.M., Wilburn W., Raynor B.D., Jamieson D. Sickle cell disease in pregnancy: twenty years of experience at Grady Memorial Hospital, Atlanta, Georgia. Am J Obstet Gynecol 2001, 184(6):1127-1130.
13. Villers M.S., Jamison M.G., De Castro L.M., James A.H. Morbidity associated with sickle cell disease in pregnancy. Am J Obstet Gynecol 2008, 199(2):e121-e125.
14. Thauvin-Robinet C., Maingueneau C., Robert E., et al. Exposure to hydroxyurea during pregnancy: a case series. Leukemia 2001, 15(8):1309-1311.
15. Lanzkron S., Strouse J.J., Wilson R., et al. Systematic review: hydroxyurea for the treatment of adults with sickle cell disease. Ann Intern Med 2008, 148(12):939-955.
16. Koshy M., Burd L., Wallace D., Moawad A., Baron J. Prophylactic red-cell transfusions in pregnant patients with sickle cell disease. A randomized cooperative study. N Engl J Med 1988, 319(22):1447-1452.
17. Howard R.J., Tuck S.M., Pearson T.C. Pregnancy in sickle cell disease in the UK: results of a multicentre survey of the effect of prophylactic blood transfusion on maternal and fetal outcome. Br J Obster Gynaecol 1995, 102(12):947-951.
18. Aitchison R.G., Marsh J.C., Hows J.M., Russell N.H., Gordon-Smith E.C. Pregnancy associated aplastic anaemia: a report of five cases and review of current management. Br J Haematol 1989, 73(4):541-545.
19. Chaplin H., Cohen R., Bloomberg G., Kaplan H.J., Moore J.A., Dorner I. Pregnancy and idiopathic autoimmune haemolytic anaemia: a prospective study during 6 months gestation and 3 months post-partum. Br J Haematol 1973, 24(2):219-229.
20. Lefkou E., Nelson-Piercy C., Hunt B.J. Evans' syndrome in pregnancy: a systematic literature review and two new cases. Eur J Obstet Gynecol Reprod Biol 2010, 149(1):10-17.
21. Burrows R.F., Kelton J.G. Incidentally detected thrombocytopenia in healthy mothers and their infants. N Engl J Med 1988, 319(3):142-145.
22. Provan D., Stasi R., Newland A.C., et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010, 115(2):168-186.
23. Webert K.E., Mittal R., Sigouin C., Heddle N.M., Kelton J.G. A retrospective 11-year analysis of obstetric patients with idiopathic thrombocytopenic purpura. Blood 2003, 102(13):4306-4311.
24. Boehlen F., Hohlfeld P., Extermann P. de Moerloose P. Maternal antiplatelet antibodies in predicting risk of neonatal thrombocytopenia. Obstet Gynecol 1999, 93(2):169-173.
25. Gernsheimer T., James A.H., Stasi R. How I treat thrombocytopenia in pregnancy. Blood 2013, 121(1):38-47.
26. van Veen J.J., Nokes T.J., Makris M. The risk of spinal haematoma following neuraxial anaesthesia or lumbar puncture in thrombocytopenic individuals. Br J Haematol 2010, 148(1):15-25.
27. Griffiths J., Sia W., Shapiro A.M., Tataryn I., Turner A.R. Laparoscopic splenectomy for the treatment of refractory immune thrombocytopenia in pregnancy. J Obstet Gynaecol Can 2005, 27(8):771-774.
28. Felbinger T.W., Posner M., Eltzschig H.K., Kodali B.S. Laparoscopic splenectomy in a pregnant patient with immune thrombocytopenic purpura. Int J Obstet Anesth 2007, 16(3):281-283.
29. Alstead E.M., Ritchie J.K., Lennard-Jones J.E., Farthing M.J., Clark M.L. Safety of azathioprine in pregnancy in inflammatory bowel disease. Gastroenterology 1990, 99(2):443-446.
30. Michel M., Novoa M.V., Bussel J.B. Intravenous anti-D as a treatment for immune thrombocytopenic purpura (ITP) during pregnancy. Br J Haematol 2003, 123(1):142-146.
31. Klink D.T., van Elburg R.M., Schreurs M.W., van Well G.T. Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development. Clin Dev Immunol 2008, 2008:271363.
32. Villa P.M., Kajantie E., Raikkonen K., et al. Aspirin in the prevention of pre-eclampsia in high-risk women: a randomised placebo-controlled PREDO trial and a meta-analysis of randomised trials. BJOG 2013, 120(1):64-74.
33. Young B.C., Levine R.J., Karumanchi S.A. Pathogenesis of preeclampsia. Ann Rev Pathol 2010, 5:173-192.
34. Young B., Levine R.J., Salahuddin S., et al. The use of angiogenic biomarkers to differentiate non-HELLP related thrombocytopenia from HELLP syndrome. J Matern Fetal Neonat Med 2010, 23(5):366-370.
35. Sibai B.M. Evaluation and management of severe preeclampsia before 34 weeks' gestation. Am J Obstet Gynecol 2011, 205(3):191-198.
36. George J.N. The association of pregnancy with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opin Hematol 2003, 10(5):339-344.
37. Keiser S.D., Boyd K.W., Rehberg J.F., et al. A high LDH to AST ratio helps to differentiate pregnancy-associated thrombotic thrombocytopenic purpura (TTP) from HELLP syndrome. J Matern Fetal Neonat Med 2012, 25(7):1059-1063.
38. Jin F., Cao M., Bai Y., Zhang Y., Yang Y., Zhang B. Therapeutic effects of plasma exchange for the treatment of 39 patients with acute fatty liver of pregnancy. Discov Med 2012, 13(72):369-373.
39. Eser B., Guven M., Unal A., et al. The role of plasma exchange in HELLP syndrome. Clin Appl Thromb Hemost 2005, 11(2):211-217.
40. Peterson J.A., McFarland J.G., Curtis B.R., Aster R.H. Neonatal alloimmune thrombocytopenia: pathogenesis, diagnosis and management. Br J Haematol Feb 6, 2013, 161(1):3-14.
41. Kjeldsen-Kragh J., Killie M.K., Tomter G., et al. A screening and intervention program aimed to reduce mortality and serious morbidity associated with severe neonatal alloimmune thrombocytopenia. Blood 2007, 110(3):833-839.
42. Bussel J.B., Zabusky M.R., Berkowitz R.L., McFarland J.G. Fetal alloimmune thrombocytopenia. N Engl J Med 1997, 337(1):22-26.
43. McQuilten Z.K., Wood E.M., Savoia H., Cole S. A review of pathophysiology and current treatment for neonatal alloimmune thrombocytopenia (NAIT) and introducing the Australian NAIT registry. Aust N Z J Obstet Gynaecol 2011, 51(3):191-198.
44. Pacheco L.D., Berkowitz R.L., Moise K.J., Bussel J.B., McFarland J.G., Saade G.R. Fetal and neonatal alloimmune thrombocytopenia: a management algorithm based on risk stratification. Obstet Gynecol 2011, 118(5):1157-1163.
45. James A.H. More than menorrhagia: a review of the obstetric and gynaecological manifestations of bleeding disorders. Haemophilia 2005, 11(4):295-307.
46. Kadir R.A., Economides D.L., Sabin C.A., Owens D., Lee C.A. Frequency of inherited bleeding disorders in women with menorrhagia. Lancet 1998, 351(9101):485-489.
47. Gilabert J., Reganon E., Vila V., et al. Congenital hypofibrinogenemia and pregnancy, obstetric and hematological management. Gynecol Obstet Invest 1987, 24(4):271-276.
48. Guy G.P., Baxi L.V., Hurlet-Jensen A., Chao C.R. An unusual complication in a gravida with factor IX deficiency: case report with review of the literature. Obstet Gynecol 1992, 80(3 Pt 2):502-505.
49. Konje J.C., Murphy P., de Chazal R., Davidson A., Taylor D. Severe factor X deficiency and successful pregnancy. Br J Obstet Gynaecol 1994, 101(10):910-911.
50. Kirtava A., Drews C., Lally C., Dilley A., Evatt B. Medical, reproductive and psychosocial experiences of women diagnosed with von Willebrand's disease receiving care in haemophilia treatment centres: a case-control study. Haemophilia 2003, 9(3):292-297.
51. MASAC guidelines for perinatal management of women with bleeding disorders and carriers of hemophilia A and B. October 31, 2009.
52. James A.H., Jamison M.G. Bleeding events and other complications during pregnancy and childbirth in women with von Willebrand disease. J Thromb Haemost 2007, 5(6):1165-1169.
53. James A.H., McLintock C., Lockhart E. Postpartum hemorrhage: when uterotonics and sutures fail. Am J Hematol 2012, 87(Suppl 1):S16-S22.
54. Charbit B., Mandelbrot L., Samain E., et al. The decrease of fibrinogen is an early predictor of the severity of postpartum hemorrhage. J Thromb Haemost 2007, 5(2):266-273.
55. Novikova N., Hofmeyr G.J. Tranexamic acid for preventing postpartum haemorrhage. Cochrane Database Syst Rev 2010 Jul 7, (7):CD007872.
56. Ahonen J. The role of recombinant activated factor VII in obstetric hemorrhage. Curr Opin Anaesthesiol 2012, 25(3):309-314.
57. Michiels J.J. Acquired hemophilia A in women postpartum: clinical manifestations, diagnosis, and treatment. Clin Appl Thromb Hemost 2000, 6(2):82-86.
58. Knoebl P., Marco P., Baudo F., et al. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost 2012, 10(4):622-631.
59. Tengborn L., Baudo F., Huth-Kuhne A., et al. Pregnancy-associated acquired haemophilia A: results from the European Acquired Haemophilia (EACH2) registry. BJOG 2012, 119(12):1529-1537.
60. Verbruggen B., van Heerde W.L., Laros-van Gorkom B.A. Improvements in factor VIII inhibitor detection: from Bethesda to Nijmegen. Semin Thromb Hemost 2009, 35(8):752-759.
61. Sborov D.W., Rodgers G.M. How I manage patients with acquired haemophilia A. Br J Haematol Feb 4, 2013, 161(2):157-165.
62. Jacobsen A.F., Skjeldestad F.E., Sandset P.M. Incidence and risk patterns of venous thromboembolism in pregnancy and puerperium-a register-based case-control study. Am J Obstet Gynecol 2008, 198(2):e231-e237.
63. Lindqvist P., Dahlback B., Marsal K. Thrombotic risk during pregnancy: a population study. Obstet Gynecol 1999, 94(4):595-599.
64. To M.S., Hunt B.J., Nelson-Piercy C. A negative D-dimer does not exclude venous thromboembolism (VTE) in pregnancy. J Obstet Gynaecol 2008, 28(2):222-223.
65. Greer I.A. Thrombosis in pregnancy: updates in diagnosis and management. Hematology/the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2012, 2012:203-207.
66. Bates S.M., Greer I.A., Middeldorp S., Veenstra D.L., Prabulos A.M., VTE Vandvik P.O. thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141(2 Suppl):e691S-e736S.
67. Greer I.A., Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 2005, 106(2):401-407.
68. Leonhardt G., Gaul C., Nietsch H.H., Buerke M., Schleussner E. Thrombolytic therapy in pregnancy. J Thromb Thrombolysis 2006, 21(3):271-276.
69. Pomp E.R., Lenselink A.M., Rosendaal F.R., Doggen C.J. Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. J Thromb Haemost 2008, 6(4):632-637.
70. Gerhardt A., Scharf R.E., Beckmann M.W., et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med 2000, 342(6):374-380.
71. Pabinger I., Grafenhofer H., Kyrle P.A., et al. Temporary increase in the risk for recurrence during pregnancy in women with a history of venous thromboembolism. Blood 2002, 100(3):1060-1062.
72. Pabinger I., Grafenhofer H., Kaider A., et al. Risk of pregnancy-associated recurrent venous thromboembolism in women with a history of venous thrombosis. J Thromb Haemost 2005, 3(5):949-954.
73. Friederich P.W., Sanson B.J., Simioni P., et al. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis. Ann Intern Med 1996, 125(12):955-960.
74. Robertson L., Wu O., Langhorne P., et al. Thrombophilia in pregnancy: a systematic review. Br J Haematol 2006, 132(2):171-196.